ation with the FAB subtype M4Eo, and some groups using an which will detect and quantitate the CBF␤/MYH11 transcripts RT-PCR have found it exclusively in M4Eo, 4 while others have associated with inv(16)(q22;p13) and have used it to study found the abnormality in cases of M4 lacking abnormal presentation and follow-up samples of acute myeloid leueosinophils. 6 The sensitivity of the PCR test has allowed it to kaemia (AML). The levels of the leukaemia-specific transcripts be used to monitor residual disease following treatment, 4, 6, 7 are expressed as a ratio to a ubiquitously expressed mRNA species (Abl) which controls for RNA degradation. This techand PCR positivity has been found in patients in long-term nique has been applied to 75 consecutive patients presenting remission.
Materials and methods Introduction

Patients
Many chromosomal translocations result in the formation of a fusion gene, with the subsequent production of a chimeric Seventy-five consecutive patients presenting with either de protein. Many of these are disease specific, and have been novo AML or tMDS were examined for the presence of the implicated in the leukaemic process. The pericentric inv(16) by RT-PCR (Table 1 ). The diagnosis of AML was made inversion of chromosome 16(p13;q22), and less frequently the according to the recommendations of the FAB, 9 and karyotype t(16;16)(p13;q22) found frequently in AML, account for 16% performed by conventional Giemsa banding techniques. of the chromosomal aberrations associated with this disease. 1 Stored material was available on two further patients who had The result of the inversion is the fusion of the core binding an inv(16) detected at presentation. Positive patients (Table 2 ) factor ␤ (CBF␤) gene on 16q22 with the smooth muscle myowere treated according to the MRC AML 10 protocol (patients sin heavy chain gene (MYH11) on 16p13. This results in the 1, 2 and 4), MRC AML 12 protocol (patients 5, 6, 7 and 8) formation of a chimeric CBF␤/MYH11 fusion gene, 2 which and one 77-year-old patient (3) was treated with a modified disrupts the normal interaction of the transcription factor comstrategy (six courses of DAT 1 + 5). One patient (7) died 8 days plex of CBF␣, ␤, and ETS. 1 A RT-PCR-based technique to detect the fusion transcript has been developed 3 and used to study patients at presentation and in clinical remission. 4 It has 
FAB classification inv16
points within the MYH11 gene, which are responsible for these, with A accounting for more than 90% of cases
detected. 4 Alternative RNA splicing of the fusion gene may
also occur, which can result in a number of different sized
products after nested PCR. 5 The inv(16) has a strong associ- after commencing induction chemotherapy on MRC AML 12. were performed. One microlitre of first round product was added using a plugged pipette to 25 l of second round buffer These protocols consist of four cycles of intensive chemotherapy based on two cycles of induction therapy, DAT mix containing 1× PCR buffer mix, 1.5 mm MgCl 2 , 1.25 mm dNTPs, 50 pmol of each internal primers, MYH11IN 5Ј-TTG (daunorubicin, Ara-C and 6 thioguanine) in the case of MRC AMLX, and ADE (Ara-C, daunorubicin and etoposide) or MAE GAG ATC CCT TTC GAA CTG G-3Ј, and CBF␤IN 5Ј-TGA AGA TAG AGA CAG GTC TCA T-3Ј, and 0.25 units of Taq (mitozantrone, Ara-C and etoposide) in MRC AMLXII, followed by MACE (amsacrine, Ara-C and etoposide) and a final polymerase. The samples were overlaid with 50 l of mineral oil and subjected to 30 cycles of PCR, under the same concourse of MiDAC (mitozantrone and intermediate dose Ara-C) in both trials. Table 2 also shows the stage of therapy at ditions as the first round PCR. Samples were visualised using a 2% agarose gel with ethidium bromide staining ( Figure 1 ). which the last follow-up sample on each patient was taken.
All cDNA samples had PCR performed for the ubiquitously expressed Abl gene to assess cDNA quality and the efficiency RNA extraction and RT-PCR analysis of the reverse transcriptase (RT) step, essentially as described Bone marrow mononuclear cells were extracted using Trizol reagent (Gibco BRL Paisley, UK). Approximately 20 g of RNA was reverse transcribed to cDNA, using random hexamers as primers, essentially as previously described. 10 Experimental precautions recommended by Kwok and Higuchi 11 were taken to avoid contamination.
First round PCR
The equivalent of 1 mg of cDNA was added to 25 l of a mixture containing, 1× PCR buffer, 1.5 mm MgCl 2 , 1.25 mm dNTPs, 50 pmol of each external primers, MI 5Ј-CTC TTC TCC TCA TTC TGC TC-3Ј, and C1 5Ј-GCA GGC AAG GTA TAT TTG AAG G-3Ј, and 0.25 units of thermoprime Taq polymerase (Advanced Biotechnologies, Leatherhead, Surrey, UK). Samples were subjected to 30 cycles of 95°C for 1 min, 62°C for 1 min, and extension at 72°C for 1 min, followed by a final extension at 72°C for 10 min. quoting of the first round product, and subsequent nested PCR by Cullis et al. 12 Samples negative for this PCR were not MYH11 primers which had been modified at their 5Ј ends by the addition of uracil (dUMP) containing linker residues. This included in the study. Negative and positive controls were included at all stages of the procedure and RT and PCR water allows site-directed ligation of the PCR product into the cloning vector pAMP1. The plasmid was linearised using the blanks were also included in all nested PCR reactions. If any discrepancies occurred within these control samples then the restriction enzyme AlwN1 (New England Biolabs, Hitchin, UK), quantitated by spectrophotometry and comparison to a PCR was considered invalid and repeated.
mass DNA ladder (Gibco BRL). Since the competitor molecule is 4425 bp in length, 1 ng contains 2.14 × 10 8 molecules. Dilutions were made from the stock competitor of 10 9 to 10
Construction of a DNA competitor molecule molecules. Briefly, logarithmic dilution were performed in molecular biology grade water with tRNA added as a carrier A PCR product was produced using a primer pair designed to amplify a 215 bp fragment from pBR322 plasmid DNA. This molecule. The competitor molecule produced a product of 307 and subsequently 265 bp when subjected to single round amplified product could be separated on the basis of size from the target sequences. The primers were modified at their 5Ј and nested PCR respectively. Patient-derived CBF␤/MYH11 PCR products were 417 and 203 bp in length. ends to include sequences corresponding to the external and internal nested primers sequences used to amplify the CBF␤/MYH11 fusion transcript as described above. These
Competitive nested RT-PCR non-plasmid sequences were amplified by the PCR, and produced a PCR fragment containing pBR322 sequence flanked Two-step nested PCR was performed as above except 2.5 l by the CBF␤/MYH11 nested primer sequences of 307 bp of patient cDNA and 2.5 l of a logarithmic dilution of the ( Figure 2 ). This product was electrophoresed through 2% agacompetitor molecule was added to 20 l of 1.25× first round rose, excised and purified using a Qiaquick spin column PCR buffer containing 1.25× PCR buffer, 1.875 mm MgCl 2 , (Gibco BRL). This PCR product was then cloned using the 1.25 mm dNTPs, 50 pmol of each external primer and 0.25 Cloneamp pAMP1 system (Gibco BRL). Briefly, this involved units of Taq polymerase. The samples were subjected to the amplification of the competitor using the external CBF␤ and same rounds of PCR as above, then transferred to a second laboratory for nested PCR.
Second round PCR
This PCR was essentially the same as the second round qualitative PCR, except that one of the internal primers used (CBF␤IN) was fluorescently labelled at its 5Ј end with HEX phosphoramidite. 13 One microlitre of first round product was added to 24 l of 1× PCR buffer, 1.5 mm MgCl 2 , 1.25 mm dNTPs, 10 pmol of each internal primer, and 0.25 ul of Taq polymerase. The samples were amplified as above for 25 cycles. The products were loaded on to a 6% denaturing polyacrylamide gel with a DNA standard in each lane and run at a constant 30 W for 3 h on a ABI 373 gene sequencer. Genescan computer software was then used to analyse the results, allowing accurate sizing and quantitation of the peak height and area of the PCR products. This allows far greater reliability in the accurate prediction of the equivalence point of the two PCR products without the need to correct for the difference in size of the competitor and target molecules (Figure 3 ).
Abl transcript quantitation
Because of variation in the transportation, storage and quality of clinical material, it was decided, rather than express the CBF␤/MYH11 transcripts as a proportion of the total RNA present, to compare it to a ubiquitously expressed gene, Abl, essentially as described by van Rhee et al 14 using the cloned competitor molecule pBK5 (Figure 2) . Quantitation of the number of Abl transcripts was determined by the equivalence of the target and competitor on 2% agarose gel electrophoresis (Figure 4) .
Validation of the CBF␤/MYH11 competitor molecule
To test the reproducibility of the method, we aliquoted follow- Single round competitive PCR to quantify the number of ABL transcripts within a sample, visualised on 2% agarose gel. Lane 1, 100 bp DNA marker; lanes 2-5, half logarithmic dilutions of ABL competitor equivalent to 3.3 × 10 5 -10 4 molecules; this cDNA sample attains equivalence at 10 4 molecules; lanes 6-10 competitor dilutions as above, sample cDNA failed to attain equivalence; lanes 11-14, competitor dilutions as before, sample shows equivalence between 10 5 and 3.3 × 10 4 molecules.
Results
Qualitative CBF␤/MYH11 PCR in AML
We performed nested RT-PCR on 75 consecutive patients presenting with either de novo AML or tMDS (Table 1) ; 6/75 (8%) were positive for the inv(16) using the RT-PCR, all were confirmed by conventional cytogenetics. Fifty-three cases were de novo AML (Table 1) and five cases had an inv(16) (10%).
Qualitative PCR data in follow-up samples RT-PCR was carried out on 17 samples from seven patients (4-80 weeks from the initiation of induction chemotherapy), derived PCR product using 10 5 molecules, at 10 4 competitor molecules, the competitor is still in excess. The 10 3 dilution shows the patient-derived PCR product to be in excess, equivalence lies between 10 4 and 10 3 molecules.
Quantitative PCR at presentation
Competitor titration assays were performed for both the CBF␤/MYH11 and Abl control transcripts in seven patients at pellets (−80°C) were extracted and reverse transcribed on four separate occasions. The ratios of CBF␤/MYH11 to Abl tranpresentation. CBF␤/MYH11 transcripts/Abl transcript levels were in the range 0.1-10/Abl transcript. scripts was always found to be concordant to within 1.0 order of magnitude (data not shown).
Linearity of the assay was assessed by performing a logarithmic dilution of presentation cellular material from two Quantitative PCR in follow-up samples patients into normal peripheral blood mononuclear cells down to a dilution of 10 −5 , reverse transcription was perforWe applied the competitor titration assay to 14 PCR positive samples from seven patients (4-22 weeks post-initiation of med, and the cDNAs from these dilutions used under identical conditions to perform the competitor titration assay. The induction chemotherapy). All patients had a significantly lower CBF␤/MYH11 transcript level than their presentation equivalence point of each dilution was determined, linearity was seen over 4.0 orders of magnitude, undiluted down to material, falling in all cases by at least 10 −2 transcripts, following the first cycle of chemotherapy. Subsequent samples on 10 −3 (data not shown).
these patients when in clinical remission gave transcript levels five patients (1) (2) (3) (4) (5) , with data from two further patients available. All patients had a decrease in transcript levels 1 month in the range 1.0 × 10 (AML M4Eo) who failed to achieve a morphological remission on the MRC AML 10 protocol. The transcript levels initially favourable prognosis. Among these is the pericentric inversion of chromosome 16(p13;q22). We have developed a robust fell over the induction period (10/ABL falling to 2 × 10 −3 /Abl at day 28) but then stayed at a constant level over the next 5 technique which can detect this abnormality at presentation and remission and if present quantitate the number of leumonths. The patient was then treated with low-dose etoposide, achieved remission and became PCR negative. Of the kaemic transcripts.
Seventy-five consecutive cases of AML have been examined cases studied three became PCR negative at 24, 51 and 80 weeks. The value of using such results clinically to predict for this abnormality by RT-PCR (46 cases of adult de novo AML, seven cases of paediatric AML and 22 cases of AML long-term survival is very difficult and this study was not designed to answer that question. In other studies of residual with evidence of trilineage dysplasia) and we found an inv 16 in 6/75 cases (8%). In cases of AML which lacked evidence disease in AML where PCR has been used to detect residual disease similar results have been found. Using t(8;21) to moniof dysplasia the incidence was 5/53 (10%) but where evidence of dysplasia was found this dropped to 1/22 (5%). Unlike other tor disease has shown that the majority of cases remain PCR positive, 16, 17 and given the good prognostic outcome of cases groups who have found the inversion 16 translocation specific to M4 FAB type, within this small population it was also seen with this translocation at least some will be long-term survivors. A similar result has been found in AML M3 where in patients with tMDS, AML M1 and AML M2.
We have, therefore, developed a quantitative competitor PML/RAR␣ transcripts are often negative in long-term survivors but the slightly more sensitive test for the reciprocal and applied it at presentation, through the course of treatment and in clinical remission. The competitor molecule is a double product can remain positive long term. 18 There is no consensus about the value of detecting residual disease using PCR in stranded DNA-based species derived by a site-specific directed PCR reaction using plasmid pBR322 as a template.
cases of AML, however, in CML there is now good data to suggest that after allogenic transplantation a rising level of Nested primer sites for the CBF␤/MYH11 were subsequently incorporated into the competitor by primer directed amplifitranscripts can predict relapse. 8 Unfortunately, in this study only one patient who completed chemotherapy has subcation. This competitor was then cloned using a commercially available PCR cloning kit (Cloneamp). The competitor titration sequently relapsed. This patient was older than the rest of the group (77 years, range 9-77 years, median 41 years) and had molecule provides an accurate and reproducible method for quantifying CBF␤/MYH11 transcripts and the assay was able evidence of myelodysplasia at presentation. She was treated with a modified schedule (six courses of DAT 1 + 5), her levels to distinguish between levels of transcript of one order of magnitude. Linearity was assessed using dilutions of presentation of transcript at 22 weeks fell to a level seen in the cases who have been long-term survivors, but she did not attain PCR material in normal bone marrow and cDNA in molecular biology water. Material from six patients at presentation negativity. Unfortunately she had no further monitoring of transcript levels and relapsed a further 30 weeks later, when (Table 1 ) and stored material from one further patient cytogenetically positive for inversion 16, was quantitated using the presumably her levels had risen significantly. This raises the issue that unlike CML where monitoring at competitor assay. The level of transcripts in all samples was in the range 0.1-10/Abl transcript, when expressed as a ratio, 6 monthly intervals is sufficient to predict relapse, cases of AML may require more frequent testing. and 2 × 10 4 -7.5 × 10 5 /g RNA, which is comparable to levels found with other translocations associated with the production of chimeric fusion transcripts. 8, 14, 15 Transcript numbers in follow-up samples were analysed in
